Think of PrEP as your daily (or on‑demand) superpower in pill form. CDC-recommended regimens like bictegravir/emtricitabine/tenofovir alafenamide (aka Biktarvy) offer rock‑solid, U=U‑level protection for HIV-negative folks at elevated risk.
In Mexico City, free PrEP is widely available at public clinics like Clínica Condesa and CAPASITS—and many private providers like PULSE CLINIC (Social Enterprise) offer fast, stigma‑free enrollment.
As of late 2024, Mexico also approved FTC/TAF‑based PrEP formulations, expanding access beyond generics.
PEP is your emergency backup if you’ve had a high-risk exposure (unprotected anal or vaginal sex, needlestick, sharing needles). Start within 72 hours—ideally ASAP—and continue for 28 days for best protection.
Clinics across CDMX (Condesa, CAPASITS, PULSE) offer same‑day PEP consults. Some walk in, some pre‑register—but if time is ticking, prioritize speed!.
As of 2025–2026, CDMX uses dolutegravir-based ART (e.g. Tivicay, Biktarvy, Movitrem) as the first line. These regimens offer fewer side effects, high resistance barriers, and simplify life—especially when viral resistance to older drugs is rising.
Public clinics—including Clínica Condesa, CAPASITS, Hospital General de México—provide universal, free ART access, even for undocumented migrants and uninsured visitors, with minimal paperwork (ID, proof of residence, CURP waiver).
Real-world voices confirm: patients at Condesa typically get Biktarvy or dolutegravir+Movitrem, have free monitoring (viral load/CD4 every six months), and get four months of meds in each pick-up. Side effects are rare and easily managed.
Service | What it is | Where to get it in CDMX |
---|---|---|
PrEP | Daily/on-demand HIV prevention pills | Clínica Condesa, CAPASITS, PULSE CLINIC, community centers |
PEP | Emergency post‑exposure pills (28 days) | Walk‑in at public/private clinics across CDMX |
ART | Ongoing HIV treatment (U=U) | Universal access at Condesa, CAPASITS, Hospital General |
Injectable options | Cabotegravir PrEP, lenacapavir trials | PULSE CLINIC and research centers (rolling out 2025‑6) |